AR080856A1 - USEFUL PIRAZOLOPIRIDINE COMPOUNDS AS QUINASE INHIBITORS - Google Patents
USEFUL PIRAZOLOPIRIDINE COMPOUNDS AS QUINASE INHIBITORSInfo
- Publication number
- AR080856A1 AR080856A1 ARP110100282A ARP110100282A AR080856A1 AR 080856 A1 AR080856 A1 AR 080856A1 AR P110100282 A ARP110100282 A AR P110100282A AR P110100282 A ARP110100282 A AR P110100282A AR 080856 A1 AR080856 A1 AR 080856A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- absent
- compounds
- alkyl
- pirazolopiridine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composiciones farmacéuticamente aceptables que comprenden dichos compuestos y métodos para usar las composiciones en el tratamiento de varias enfermedades, condiciones o trastornos y procesos para preparar compuestos. Reivindicacion 1: Un compuesto representado por la formula estructural (1) o una sal farmacéuticamente aceptable del mismo, donde T es -NH- o está ausente, cada Jc1 y Jc2 es independientemente -CN, -F, -Cl, -OR, -CH2OR, o -CF3; cada U1, U2 y U3 es independientemente -H, Z, o Jb donde no más de uno entre U1, U2 y U3 es -H; o dos de U1, U2 y U3 se unen entre sí para formar un anillo de cicloalquilo C1-6 que tiene 0-1 heteroátomos independientemente sustituidos con uno o más Je; Z es Y2-Q2; Y2 está ausente o es alquilo C1-6 opcionalmente e independientemente sustituido con uno o más Jd; Q2 está ausente o es un cicloalquilo C3-8 que tiene 0-1 heteroátomos opcionalmente e independientemente substituido con uno o más Je, donde no ambos Y2 y Q2 están ausentes; cada Jb es independientemente -F, -OR, -CN, -CF3, -N(R)2, -C(O)N(R)2, alquilo C1-6 opcionalmente e independientemente substituido con uno o más Ja; cada Ja es independientemente -F, -OR, -N(R)2, o -C(O)N(R) 2; cada Jd es independientemente -OR, -CN, -C(O)N(R)2, -N(R)2 o F; cada Je es independientemente alquilo C1-6, -OR, - N(R)2CF3, o F; cada R es -H o alquilo C1-6; y donde existe un centro quiral en el átomo indicado por *.Pharmaceutically acceptable compositions comprising said compounds and methods for using the compositions in the treatment of various diseases, conditions or disorders and processes for preparing compounds. Claim 1: A compound represented by structural formula (1) or a pharmaceutically acceptable salt thereof, where T is -NH- or is absent, each Jc1 and Jc2 is independently -CN, -F, -Cl, -OR, - CH2OR, or -CF3; each U1, U2 and U3 is independently -H, Z, or Jb where no more than one between U1, U2 and U3 is -H; or two of U1, U2 and U3 join together to form a C1-6 cycloalkyl ring having 0-1 heteroatoms independently substituted with one or more Je; Z is Y2-Q2; Y2 is absent or is C1-6 alkyl optionally and independently substituted with one or more Jd; Q2 is absent or is a C3-8 cycloalkyl having 0-1 heteroatoms optionally and independently substituted with one or more Je, where not both Y2 and Q2 are absent; each Jb is independently -F, -OR, -CN, -CF3, -N (R) 2, -C (O) N (R) 2, C1-6 alkyl optionally and independently substituted with one or more Ja; each Ja is independently -F, -OR, -N (R) 2, or -C (O) N (R) 2; each Jd is independently -OR, -CN, -C (O) N (R) 2, -N (R) 2 or F; each Je is independently C1-6 alkyl, -OR, - N (R) 2CF3, or F; each R is -H or C1-6 alkyl; and where there is a chiral center in the atom indicated by *.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29864910P | 2010-01-27 | 2010-01-27 | |
US41042610P | 2010-11-05 | 2010-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080856A1 true AR080856A1 (en) | 2012-05-16 |
Family
ID=44088992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100282A AR080856A1 (en) | 2010-01-27 | 2011-01-27 | USEFUL PIRAZOLOPIRIDINE COMPOUNDS AS QUINASE INHIBITORS |
Country Status (9)
Country | Link |
---|---|
US (1) | US9067932B2 (en) |
EP (1) | EP2528917B1 (en) |
JP (1) | JP5769733B2 (en) |
CN (1) | CN102858769A (en) |
AR (1) | AR080856A1 (en) |
AU (1) | AU2011209726A1 (en) |
CA (1) | CA2787315A1 (en) |
MX (1) | MX2012008644A (en) |
WO (1) | WO2011094273A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
EP2313372B1 (en) | 2008-08-06 | 2013-04-10 | Vertex Pharmaceuticals Incorporated | Aminopyridine kinase inhibitors |
WO2011094290A1 (en) * | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrimidine kinase inhibitors |
EP2528916A1 (en) * | 2010-01-27 | 2012-12-05 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
ES2851724T3 (en) * | 2013-09-18 | 2021-09-08 | Epiaxis Therapeutics Pty Ltd | Stem cell modulation |
WO2016029262A1 (en) * | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
JP2021502405A (en) * | 2017-11-08 | 2021-01-28 | エピアクシス セラピューティクス プロプライエタリー リミテッド | Immunogenic compositions and their use |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3853898A (en) | 1971-07-20 | 1974-12-10 | Sandoz Ag | 3-(2-substituted amino) pyridyl-phenyl ketone imines |
US4988705A (en) | 1985-06-13 | 1991-01-29 | Schering Corporation | Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives |
FR2601015B1 (en) | 1986-07-04 | 1988-08-05 | Rhone Poulenc Sante | NOVEL 1H, 3H-PYRROLO (1,2-C) THIAZOLE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
DE3827253A1 (en) | 1987-08-20 | 1989-03-02 | Sandoz Ag | Esters and amides of cyclic carboxylic acids and cyclic alcohols and amines, processes for their preparation and therapeutic compositions containing them |
CA1339423C (en) | 1988-09-14 | 1997-09-02 | Yuji Ono | Pyridine compounds and pharmaceutical use thereof |
US5100768A (en) | 1989-05-09 | 1992-03-31 | Kabushiki Kaisha Toshiba | Photosensitive composition |
JPH03206450A (en) | 1990-01-09 | 1991-09-09 | Fuji Photo Film Co Ltd | Novel dye forming coupler and silver halide color photographic sensitive material formed by using this coupler and processing method for this material |
US5308854A (en) | 1990-06-18 | 1994-05-03 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
JPH05331163A (en) | 1991-03-26 | 1993-12-14 | Kumiai Chem Ind Co Ltd | Pyridine derivative and herbicide |
UA44220C2 (en) | 1991-11-07 | 2002-02-15 | Агрево Юк Лімітед | SULPHONAMIDES WITH HERBICIDAL ACTIVITY, METHOD OF OBTAINING THEM, HERBICIDAL COMPOSITION AND METHOD OF WEED CONTROL |
US5476750A (en) | 1992-12-29 | 1995-12-19 | Hoechst Celanese Corporation | Metal ion reduction in the raw materials and using a Lewis base to control molecular weight of novolak resin to be used in positive photoresists |
DE69404306T2 (en) | 1993-05-28 | 1997-10-30 | Pfizer | METHOD FOR THE PRODUCTION AND OPTICAL RESOLUTION OF 2-PHENYL-3-AMINOPIPERIDINE |
CA2133355A1 (en) | 1993-10-04 | 1995-04-05 | Itaru Nitta | Method for producing polypeptide |
WO1995032963A1 (en) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylazole compound and thienotriazolodiazepine compound |
NZ291507A (en) | 1994-08-29 | 1997-12-19 | Yamanouchi Pharma Co Ltd | 1,8-naphthyridine derivatives; medicaments |
US5646330A (en) | 1995-02-17 | 1997-07-08 | Ciba-Geigy Corporation | Production of enantiomerically enriched ortho-substituted α,α-diaromatic methanols |
US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
NZ322197A (en) | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
US6303655B1 (en) | 1997-04-18 | 2001-10-16 | Kissei Pharmaceutical Co., Ltd. | Preventives or remedies for diseases affecting excessive proliferation of retinal pigment epithelial cells |
WO1998057957A1 (en) | 1997-06-18 | 1998-12-23 | Nissan Chemical Industries, Ltd. | Pyridine compounds and herbicides |
US6452008B2 (en) | 1998-02-25 | 2002-09-17 | Sumitomo Pharmaceuticals Company, Limited | Pyridone derivatives and process for preparing the same |
US6225329B1 (en) | 1998-03-12 | 2001-05-01 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPases) |
GB9908410D0 (en) | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
WO2001083492A1 (en) | 2000-05-02 | 2001-11-08 | Newbiotics, Inc. | Improved beta-lactam antibiotics |
AR029289A1 (en) | 2000-07-05 | 2003-06-18 | Ishihara Sangyo Kaisha | DERIVED FROM BENZOILPIRIDINE OR ITS SALT, FUNGICIDE THAT CONTAINS IT AS AN ACTIVE INGREDIENT, ITS PRODUCTION AND INTERMEDIARY PROCESS TO PRODUCE IT |
DE10035908A1 (en) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | New heteroaryl derivatives and their use as medicines |
US20040058903A1 (en) | 2000-10-05 | 2004-03-25 | Hisashi Takasugi | Benzamide compounds as apo b secretion inhibitors |
ES2200617B1 (en) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | DERIVATIVES OF UREA AS ANTAGONISTS OF INTEGRINAS ALPHA 4. |
GB2373245A (en) | 2001-03-12 | 2002-09-18 | Bayer Ag | Pyridinyl pyrazoles and their use for the treatment of COPD |
JO3429B1 (en) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | Hiv inhibiting pyrimidines derivatives |
CN100491371C (en) | 2001-11-01 | 2009-05-27 | 詹森药业有限公司 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (GSK3 inhibitors) |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
CA2485681C (en) | 2002-05-24 | 2012-10-16 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
AU2003259749A1 (en) | 2002-08-12 | 2004-02-25 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
AP2005003365A0 (en) | 2003-02-07 | 2005-09-30 | Janssen Pharmaceutica Nv | Hiv inhibiting 1, 2, 4-triazines. |
DE602004013427T2 (en) | 2003-02-28 | 2009-06-04 | Schering Corp. | BIARYLTETRAHYDROISOCHINOLINE PIPERIDINE AS SELECTIVE MCH RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ADIPOSITAS AND RELATED DISEASES |
US20050203067A1 (en) | 2003-05-12 | 2005-09-15 | Hresko Michelle C. | Pesticidal compositions and methods |
WO2005000813A1 (en) | 2003-05-30 | 2005-01-06 | Imclone Systems Incorporated | Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors |
NZ544697A (en) | 2003-07-22 | 2009-03-31 | Janssen Pharmaceutica Nv | Quinolinone derivatives as inhibitors of c-fms kinase |
EP1668011B1 (en) | 2003-09-25 | 2011-03-02 | Janssen Pharmaceutica NV | Hiv replication inhibiting purine derivatives |
CA2542031A1 (en) | 2003-10-10 | 2005-04-21 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
ATE455765T1 (en) | 2003-12-22 | 2010-02-15 | Basilea Pharmaceutica Ag | ARYLOXY AND ARYLTHIOXYACETOPHENONE COMPOUNDS FOR TREATING CANCER |
US7507826B2 (en) * | 2004-03-30 | 2009-03-24 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
UA87494C2 (en) * | 2004-03-30 | 2009-07-27 | Вертекс Фармасьютикалс Инкорпорейтед | Azaindoles useful as inhibitors of jak and other protein kinases |
EP1756108A2 (en) | 2004-04-02 | 2007-02-28 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
WO2005111001A1 (en) | 2004-05-19 | 2005-11-24 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
EP2239262A3 (en) * | 2004-07-27 | 2011-10-19 | SGX Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
EP1781654A1 (en) | 2004-07-27 | 2007-05-09 | SGX Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US20090227799A1 (en) | 2004-08-09 | 2009-09-10 | Kazutaka Nakamoto | Novel Antimalarial Agent Containing Heterocyclic Compound |
EP1807424B1 (en) | 2004-10-29 | 2012-04-18 | Abbott Laboratories | Novel kinase inhibitors |
WO2006058120A1 (en) * | 2004-11-22 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Bicyclic inhibitors or rho kinase |
JP5190270B2 (en) | 2005-01-14 | 2013-04-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Pyrazolopyrimidines as cell cycle kinase inhibitors |
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
KR100973609B1 (en) | 2005-03-23 | 2010-08-03 | 에프. 호프만-라 로슈 아게 | Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists |
ATE511843T1 (en) | 2005-04-04 | 2011-06-15 | Eisai R&D Man Co Ltd | DIHYDROPYRIDINE COMPOUNDS FOR NEURODEGENERATIVE DISEASES AND DEMENTIA |
WO2006109876A1 (en) | 2005-04-08 | 2006-10-19 | Eisai R & D Management Co., Ltd. | Agent for treating involuntary movement |
KR20080016643A (en) | 2005-05-16 | 2008-02-21 | 아이알엠 엘엘씨 | Pyrrolopyridine derivatives as protein kinase inhibitors |
SG151327A1 (en) * | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
DE102006029447A1 (en) * | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituted imidazo [1,2b] pyridazines, their preparation and use as pharmaceuticals |
US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
EP2778155A1 (en) | 2007-01-31 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
JP2010526120A (en) * | 2007-05-09 | 2010-07-29 | ノバルティス アーゲー | Substituted imidazopyridazines as PI3K lipid kinase inhibitors |
JP4946728B2 (en) | 2007-08-23 | 2012-06-06 | 三菱電機株式会社 | Power amplifier |
MX2010004819A (en) * | 2007-11-02 | 2010-07-05 | Vertex Pharma | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta. |
AU2009274023A1 (en) * | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
US8569337B2 (en) * | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
WO2010011756A1 (en) * | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
CA2731432A1 (en) * | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
MX2011000834A (en) * | 2008-07-23 | 2011-04-05 | Vertex Pharma | Pyrazolopyridine kinase inhibitors. |
EP2528916A1 (en) * | 2010-01-27 | 2012-12-05 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
-
2011
- 2011-01-26 JP JP2012551251A patent/JP5769733B2/en active Active
- 2011-01-26 CA CA2787315A patent/CA2787315A1/en not_active Abandoned
- 2011-01-26 MX MX2012008644A patent/MX2012008644A/en active IP Right Grant
- 2011-01-26 WO PCT/US2011/022522 patent/WO2011094273A1/en active Application Filing
- 2011-01-26 US US13/014,505 patent/US9067932B2/en active Active
- 2011-01-26 AU AU2011209726A patent/AU2011209726A1/en not_active Abandoned
- 2011-01-26 EP EP11703958.6A patent/EP2528917B1/en active Active
- 2011-01-26 CN CN2011800130461A patent/CN102858769A/en active Pending
- 2011-01-27 AR ARP110100282A patent/AR080856A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2013518111A (en) | 2013-05-20 |
US9067932B2 (en) | 2015-06-30 |
WO2011094273A1 (en) | 2011-08-04 |
CA2787315A1 (en) | 2011-08-04 |
EP2528917B1 (en) | 2016-10-19 |
CN102858769A (en) | 2013-01-02 |
JP5769733B2 (en) | 2015-08-26 |
US20120071494A1 (en) | 2012-03-22 |
AU2011209726A1 (en) | 2012-08-09 |
MX2012008644A (en) | 2012-11-23 |
EP2528917A1 (en) | 2012-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR080856A1 (en) | USEFUL PIRAZOLOPIRIDINE COMPOUNDS AS QUINASE INHIBITORS | |
AR089134A1 (en) | ARILOS AND INHIBITING BICYCLE HETEROARILS OF THE SODIUM CHANNELS | |
PE20210667A1 (en) | BENZAMIDE DERIVATIVES FOR INHIBITION OF ABL1, ABL2 AND BCR-ABL1 ACTIVITY | |
AR092270A1 (en) | SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B | |
CY1122610T1 (en) | ALKOXY PYRAZOLES AS SOLVENT ACTIVATORS OF WANYLATE CYCLES | |
AR102361A1 (en) | METHYL-QUINOLINE COMPOUNDS USEFUL TO INHIBIT THE MICROSOMAL PROSTAGLANDIN E2 SYNTHESA-1 | |
PE20141209A1 (en) | INFLUENZA VIRUS REPLICATION INHIBITORS | |
RU2018122564A (en) | APPLICATION OF FLECAINIDE AS ANTI-CONNEXIN PRODUCT AND METHOD FOR POTENTIATING EFFECTS OF PSYCHOTROPIC MEDICINES | |
AR082101A1 (en) | ACIDS OF HYDROXYPHENYLHEXINOIC ARYLOXIALQUYLENE-REPLACED, PROCEDURE FOR PREPARATION AND USE AS A MEDICINAL PRODUCT | |
AR093659A1 (en) | CYCLE DERIVATIVES OF NUCLEOSIDS AND USES OF THE SAME | |
AR078151A1 (en) | CONJUGATES OF FATTY ACIDS AND NIACINA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF METABOLIC DISEASES. | |
AR088000A1 (en) | DERIVATIVES OF PIRAZOLQUINOLINONA, ITS PREPARATION AND THERAPEUTIC USE | |
EA201490320A1 (en) | TETRAHYDROPYRIDOPYRIDINE AND TETRAHYDROPYRIDOPYRIMIDINE COMPOUNDS AND THEIR APPLICATION AS MODEL C5A RECEPTOR MODULATORS | |
EA201390934A1 (en) | COMPOSITIONS AND METHODS OF FXR MODULATION | |
EA201591775A1 (en) | SUBSTITUTED AROMATIC COMPOUNDS AND RELATED METHOD FOR THE TREATMENT OF FIBROSIS | |
BR112013023517A2 (en) | "leukotriene production inhibitors, their uses, and pharmaceutical composition" | |
CO6230986A2 (en) | COMPOSITE OF 4-PYRIDINONE AND ITS USE FOR CANCER | |
CL2011003302A1 (en) | Compounds derived from alkyl sulfonic acid amide; pharmaceutical composition; use of the compounds as modulators of glutamate dysfunction to prevent or treat neurological and psychiatric disorders such as schizophrenia, Alzheimer's disease, attention deficit / hyperactivity disorders, hearing loss, among others. | |
AR078321A1 (en) | DERIVATIVES OF 2,4'-BIPIRIDINE AS KINASE INHIBITORS (CDK9) | |
BR112014010401A8 (en) | HEPATITIS C VIRUS ROD-LIKE INHIBITORS CONTAINING THE FRAGMENT {2-[4-(BIPHENYL-4-IL)-1H-IMIDAZO-2-IL] PYRROLIDINE-1-CARBONYLMETHYL}AMINE | |
MX361457B (en) | Carbazole-containing sulfonamides as cryptochrome modulators. | |
EA201600241A1 (en) | SUBSTITUTED (2R, 3R, 5R) -3-HYDROXY- (5-PYRIMIDIN-1-IL) TETRAHYDROFURAN-2-ILMETYL ARIL PHOSPHORAMIDATES | |
RU2015125591A (en) | BENZYL SULPHONAMIDE DERIVATIVES AS RORc MODULATORS | |
EA201590562A1 (en) | БЕНЗАМИДЫ | |
BR112015004523A2 (en) | tetracycline compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |